Dermapharm Holding SE - Asset Resilience Ratio
Dermapharm Holding SE (DMP) has an Asset Resilience Ratio of 1.23% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check DMP strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Dermapharm Holding SE's Asset Resilience Ratio has changed over time. See Dermapharm Holding SE balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Dermapharm Holding SE's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Dermapharm Holding SE market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €28.06 Million | 1.23% |
| Total Liquid Assets | €28.06 Million | 1.23% |
Asset Resilience Insights
- Limited Liquidity: Dermapharm Holding SE maintains only 1.23% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Dermapharm Holding SE Industry Peers by Asset Resilience Ratio
Compare Dermapharm Holding SE's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Dermapharm Holding SE (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Dermapharm Holding SE.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.03% | €736.00K ≈ $860.46K |
€2.20 Billion ≈ $2.58 Billion |
+0.01pp |
| 2024-12-31 | 0.02% | €511.00K ≈ $597.41K |
€2.08 Billion ≈ $2.43 Billion |
-7.36pp |
| 2023-12-31 | 7.38% | €159.50 Million ≈ $186.47 Million |
€2.16 Billion ≈ $2.53 Billion |
-4.11pp |
| 2022-12-31 | 11.50% | €162.43 Million ≈ $189.89 Million |
€1.41 Billion ≈ $1.65 Billion |
-0.81pp |
| 2021-12-31 | 12.30% | €173.12 Million ≈ $202.40 Million |
€1.41 Billion ≈ $1.64 Billion |
+2.40pp |
| 2020-12-31 | 9.91% | €121.30 Million ≈ $141.81 Million |
€1.22 Billion ≈ $1.43 Billion |
-1.17pp |
| 2019-12-31 | 11.08% | €115.77 Million ≈ $135.34 Million |
€1.04 Billion ≈ $1.22 Billion |
-19.23pp |
| 2018-12-31 | 30.31% | €213.57 Million ≈ $249.69 Million |
€704.58 Million ≈ $823.73 Million |
+28.71pp |
| 2017-12-31 | 1.60% | €6.64 Million ≈ $7.76 Million |
€415.30 Million ≈ $485.53 Million |
+0.36pp |
| 2016-12-31 | 1.23% | €3.85 Million ≈ $4.50 Million |
€311.70 Million ≈ $364.41 Million |
+1.22pp |
| 2015-12-31 | 0.01% | €29.00K ≈ $33.90K |
€296.67 Million ≈ $346.83 Million |
-0.03pp |
| 2014-12-31 | 0.04% | €120.00K ≈ $140.29K |
€330.60 Million ≈ $386.50 Million |
+0.00pp |
| 2013-12-31 | 0.03% | €120.00K ≈ $140.29K |
€349.98 Million ≈ $409.16 Million |
-- |
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers br… Read more